<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675452</url>
  </required_header>
  <id_info>
    <org_study_id>20150161</org_study_id>
    <secondary_id>2015-004777-32</secondary_id>
    <nct_id>NCT02675452</nct_id>
  </id_info>
  <brief_title>AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least one dose level of AMG 176 will achieve acceptable safety and tolerability in&#xD;
      subjects with relapsed or refractory multiple myeloma and subjects with relapsed or&#xD;
      refractory acute myeloid leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and&#xD;
      dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory&#xD;
      multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia The study&#xD;
      will be conducted in four parts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Anticipated">June 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 7, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Myeloma (MM) Part 1a Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the maximum tolerated dose (MTD) for two-consecutive days per week dosing schedule (QD2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Incidence of clinically significant changes in electrocardiograms (ECGs)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Pharmacokinetic parameters for AMG 176: maximum observed concentration (Cmax)</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the pharmacokinetics (PK) of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Pharmacokinetic parameters for AMG 176: area under the concentration-time curve (AUC)</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Pharmacokinetic parameters for AMG 176: clearance (CL)</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1a Pharmacokinetic parameters for AMG 176: half-life (t1/2)</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Incidence of DLTs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a once weekly (QW) dosing schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Incidence of clinically significant changes in ECGs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Pharmacokinetic parameters for AMG 176: Cmax</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Pharmacokinetic parameters for AMG 176: AUC</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Pharmacokinetic parameters for AMG 176: CL</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MM Part 1b Pharmacokinetic parameters for AMG 176: t1/2</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Myeloid Leukemia (AML) Part 3a Incidence of DLTs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Incidence of clinically significant changes in ECGs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Pharmacokinetic parameters for AMG 176: Cmax</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Pharmacokinetic parameters for AMG 176: AUC</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Pharmacokinetic parameters for AMG 176: CL</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3a Pharmacokinetic parameters for AMG 176: t1/2</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QD2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Incidence of DLTs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Incidence of clinically significant changes in ECGs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Pharmacokinetic parameters for AMG 176: Cmax</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Pharmacokinetic parameters for AMG 176: AUC</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Pharmacokinetic parameters for AMG 176: CL</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3b Pharmacokinetic parameters for AMG 176: t1/2</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy QW</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Incidence of DLTs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Incidence of clinically significant changes in ECGs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Pharmacokinetic parameters for AMG 176: Cmax</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Pharmacokinetic parameters for AMG 176: AUC</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Pharmacokinetic parameters for AMG 176: CL</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3c Pharmacokinetic parameters for AMG 176: t1/2</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: Cmax</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: AUC</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: CL</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: t1/2</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Incidence of DLTs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the maximum tolerated combination dose (MTCD) of AMG 176 in combination with azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Incidence of clinically significant changes in ECGs</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: Cmax</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 and azacitidine when administered in combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: AUC</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 and azacitidine when administered in combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: CL</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 and azacitidine when administered in combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: t1/2</measure>
    <time_frame>1 month on treatment</time_frame>
    <description>Evaluate the PK of AMG 176 and azacitidine when administered in combination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MM Part 1a BAX and caspase 3 expression in circulating monocytes and /or circulating monocyte counts</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Demonstrate inactivation of myeloid cell leukemia sequence 1 (MCL1) by the increase of active Bcl 2 associated X protein (BAX) and caspase 3 in circulating monocytes and/or the decrease of circulating monocytes in AMG 176 QD2 treated subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1a Overall response (OR) according to International Myeloma Working Group uniform response criteria (IMWG-URC) for MM subjects</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1a Progression-free survival (PFS)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1a Time to response</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1a Duration of response (DOR)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1b BAX and caspase 3 expression in circulating monocytes and /or circulating monocyte counts</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Demonstrate inactivation of MCL1 by the increase of active BAX and caspase 3 in circulating monocytes and /or the decrease of circulating monocytes in AMG 176 QW treated subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1b Overall response (OR) according to IMWG-URC for MM subjects</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1b Progression free survival (PFS)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1b Time to response</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Part 1b Duration of response (DOR)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3a, 3b and 3c Overall response (OR) according to the 2017 European Leukemia Net (ELN) criteria (Döhner et al, 2017)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3a, 3b and 3c Event free survival (EFS)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3a, 3b and 3c Time to response</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3a, 3b and 3c Duration of response (DOR)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3d Incidence of treatment-emergent adverse events</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3d Incidence of clinically significant changes in vital signs</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3d Incidence of clinically significant changes in ECGs</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 3d Incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>3 weeks on treatment</time_frame>
    <description>Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 4 Overall response (OR) according to the 2017 ELN criteria in AML subjects</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 4 Event free survival (EFS)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 4 Time to response</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML Part 4 Duration of response (DOR)</measure>
    <time_frame>6 months on treatment</time_frame>
    <description>Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">127</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <condition>Relapsed or Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>AMG 176 - Part 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 3c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 3d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3d - Participants in the United States with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW), for 3 weeks, in combination with itraconazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break, in combination with azacitidine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 176</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>AMG 176 - Part 1a</arm_group_label>
    <arm_group_label>AMG 176 - Part 1b</arm_group_label>
    <arm_group_label>AMG 176 - Part 3a</arm_group_label>
    <arm_group_label>AMG 176 - Part 3b</arm_group_label>
    <arm_group_label>AMG 176 - Part 3c</arm_group_label>
    <arm_group_label>AMG 176 - Part 3d</arm_group_label>
    <arm_group_label>AMG 176 - Part 4</arm_group_label>
    <other_name>Study Investigational Product (IP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Non-investigational product</description>
    <arm_group_label>AMG 176 - Part 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Non-investigational product</description>
    <arm_group_label>AMG 176 - Part 3d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  For participants in Japan only: if a participant is younger than 20 years at the time&#xD;
             of signing the informed consent form, informed consent must be obtained from both the&#xD;
             participant and his/her legal representative&#xD;
&#xD;
          -  (Multiple myeloma subjects) Pathologically documented, multiple myeloma relapsed or&#xD;
             refractory disease after at least 2 lines of therapy&#xD;
&#xD;
          -  (MM subjects only) Measurable disease per the IMWG response criteria&#xD;
&#xD;
          -  (Acute myeloid leukemia subjects) AML as defined by the World Health Organization&#xD;
             (WHO) Classification persisting or recurring following one or more treatment courses,&#xD;
             and for participants in Japan, determined by the investigator to be not eligible for&#xD;
             approved anticancer drug therapy in Japan; EXCEPT acute promyelocytic leukemia.&#xD;
&#xD;
          -  (AML subjects only) More than 5% blasts in bone marrow and Circulating white blood&#xD;
             cells (WBCs) &lt; 25,000/ul.&#xD;
&#xD;
          -  Must be willing and able to undergo a core bone marrow biopsy (MM subjects only) and&#xD;
             bone marrow aspirate (MM and AML subjects) at screening.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2,&#xD;
&#xD;
          -  (MM subjects only) Satisfactory hematological function without transfusion or growth&#xD;
             factor support&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months, in the opinion of the investigator&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate cardiac function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test&#xD;
&#xD;
          -  Other inclusion criteria may apply&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Previously received an allogeneic stem cell transplant within 6 months OR having&#xD;
             received immunosuppressive therapy within the last three months OR having signs or&#xD;
             symptoms of acute or chronic graft-versus-host disease&#xD;
&#xD;
          -  Autologous stem cell transplant less than 90 days prior to study day 1&#xD;
&#xD;
          -  (MM subjects only) Multiple myeloma with IgM subtype&#xD;
&#xD;
          -  (MM subjects only) POEMS syndrome&#xD;
&#xD;
          -  (MM subjects only) Existing plasma cell leukemia&#xD;
&#xD;
          -  (MM subjects only) Waldenstrom's macroglobulinemia&#xD;
&#xD;
          -  (MM subjects only) Amyloidosis&#xD;
&#xD;
          -  (Acute myeloid leukemia Part 4 only) Presence of advanced malignant hepatic tumors&#xD;
             with baseline albumin &lt; 3 g/dL&#xD;
&#xD;
          -  Infection requiring intravenous anti-infective treatments within 1 week of study&#xD;
             enrollment (day 1)&#xD;
&#xD;
          -  Myocardial infarction within 6 months of enrollment, symptomatic congestive heart&#xD;
             failure (New York Heart Association &gt; class II)&#xD;
&#xD;
          -  History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 6&#xD;
             months prior to enrollment&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study. Other&#xD;
             investigational procedures while participating in this study will be allowed if&#xD;
             approved by Amgen medical monitor&#xD;
&#xD;
          -  Participants with elevated cardiac troponin above the manufacturer's 99th percentile&#xD;
             upper reference limit for ADVIA Centaur XP assay at screening performed by the central&#xD;
             laboratory&#xD;
&#xD;
          -  Participants with evidence of recent cardiac injury at screening based on creatine&#xD;
             kinase-muscle/brain (CK-MB), N-terminal prohormone of brain natriuretic peptide&#xD;
             (NT-pro-BNP), and electrocardiogram (ECG)&#xD;
&#xD;
          -  Other exclusion criteria may apply&#xD;
&#xD;
          -  (Acute myeloid leukemia Part 3d only) History of QT prolongation, torsades de pointes,&#xD;
             ventricular tachycardia and cardiac arrest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Okayama Medical Center</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

